CD274 and triple-negative breast carcinoma: Pembrolizumab, a PD-L1 inhibitor, has been tested in early phase clinical trials for metastatic PD-L1-positive triple-negative breast cancer (TNBC) and has shown clinical benefits in approximately 20% of patients (Nanda et al., 2016).